Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!
Back in 2008, Velcade (bortezomib) was just being approved to treat patients with multiple myeloma. A combination called RVd — Revlimid (lenalidomide), Velcade and dexamethasone – eventually became standard of care for this patient population after it showed promising results in the SWOG S077 trial.
However, not everyone can tolerate this combination, so a new option, “RVd lite,” is being explored.
Since, 2018 has also had some major Food and Drug Administration (FDA) moves, pushing the field far beyond where it was a decade ago.
The year has been an exciting one for the treatment of myeloma, and there is sure to be even more advances made in 2019. To read more and stay up to date with all myeloma news, visit https://www.curetoday.com/tumor/myeloma